Atara Biotherapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Cokey Nguyen

Geschäftsführender

US$2.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	23.7%
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.8yrs

Jüngste Management Updates

Recent updates

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Jul 21

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 03

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Sep 28

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Aug 17

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Cokey Nguyen im Vergleich zu den Einnahmen von Atara Biotherapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$181m
Mar 31 2024	n/a	n/a	-US$233m
Dec 31 2023	US$2m	US$540k	-US$276m

Vergütung im Vergleich zum Markt: PascalDie Gesamtvergütung ($USD4.38M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD659.68K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Cokey mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Cokey Nguyen (51 yo)

no data

Amtszeit

US$2,277,691

Vergütung

Dr. Anhco Nguyen, Ph D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at A...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anhco Nguyen	President	no data	US$2.28m	0.22% $ 100.1k
K. Murugan	Executive VP & Chief Legal Officer	4.4yrs	US$2.31m	0.19% $ 87.7k
Eric Hyllengren	Executive VP & Chief Financial Officer	1.4yrs	keine Daten	0.16% $ 72.9k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	keine Daten	keine Daten
Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	4yrs	keine Daten	0.14% $ 62.0k
Dan Maziasz	Executive VP & Chief Business Officer	3.7yrs	keine Daten	keine Daten
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

49.5yo

Durchschnittliches Alter

Erfahrenes Management: ATRADas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anhco Nguyen	President	no data	US$2.28m	0.22% $ 100.1k
William Heiden	Independent Director	8.8yrs	US$237.23k	0.11% $ 49.1k
Matthew Fust	Independent Director	10.5yrs	US$239.73k	0.037% $ 16.8k
Carol Gallagher	Lead Independent Director	11.7yrs	US$260.23k	0.30% $ 136.5k
Gregory Ciongoli	Independent Director	no data	keine Daten	keine Daten
Ameet Mallik	Independent Director	3.1yrs	US$219.52k	0.014% $ 6.6k
Maria Roncarolo	Independent Director	4.3yrs	US$229.73k	0.022% $ 10.2k
Pascal Touchon	Chairman of the Board	5.3yrs	US$4.38m	0.50% $ 228.8k

4.8yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: ATRADie Vorstandsmitglieder gelten als erfahren (8.5 Jahre durchschnittliche Amtszeit).

Atara Biotherapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

President notifies of intention to sell stock

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Independent Director recently bought US$101k worth of stock

Recent updates

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

New major risk - Share price stability

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Price target decreased by 71% to US$30.33

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 61%

Price target decreased by 20% to US$14.74

Price target decreased by 13% to US$16.43

Atara Biotherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 11%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%